Sponsor: Kronos Bio
Sponsor Study ID: KB-ENTO-3001
Study Title: Phase 3 Trial Using the SYK inhibitor, Entospletinib, in Combination with Standard Induction and Consolidation Chemotherapy in Newly Diagnosed, NPM1 Mutated Acute Myelogenous Leukemia
CTO #: 103389
NCT Number: NCT05020665
Phase: III
Protocol Type: Treatment
Age Group: Adults
Disease Sites: Myeloid and Monocytic Leukemia
Study Objectives: The primary objective of this study is to evaluate the efficacy of entospletinib (ENTO) compared to placebo when added to chemotherapy in previously untreated nucleophosmin-1 mutated (NPM1-m) acute myeloid leukemia (AML), as defined by the rate of molecularly defined measurable residual disease (MRD).